China’s Biotech Surge at ASCO 2026 Challenges US Dominance
CHICAGO — A record-breaking wave of Chinese-led clinical research at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is signaling a fundamental shift in global drug development, with China’s rapidly maturing biotechnology sector challenging decades of American dominance in pharmaceutical innovation.
Chinese researchers presented 95 abstracts at this year’s conference — nearly double the 48 presented in 2024 and up from 72 in 2025 — with 12 studies earning the prestigious Late-Breaking Abstract designation reserved for high-impact research with the potential to shift clinical practice, according to China Daily Brief. The surge reflects a strategic transformation that has seen China evolve from a low-cost manufacturer of generic drugs into a primary source of intellectual capital in oncology research.
A Watershed Moment for Chinese Biotech
“This tells us that the Chinese biotech industry has arrived,” said Dr. Otis Brawley, a Bloomberg Distinguished Professor at Johns Hopkins University who has attended ASCO every year since 1989, as quoted by The New York Times.
The numbers bear out his assessment. China has already surpassed the United States in total drug clinical trials, listing over 7,100 trials compared to roughly 6,000 in the U.S., according to a 2025 report from GlobalData cited by Axios. Leading the charge are STAR Market-listed innovators such as BeiGene, Biokin Pharmaceutical, and Dizal Pharma, which are moving beyond incremental “fast-follower” strategies to develop “first-in-class” and “best-in-class” therapies targeting lung, breast, gastrointestinal, and hematological cancers.
Landmark Pfizer-Innovent Partnership
The most striking validation of China’s biotech ascent came on May 28, when Pfizer Inc. and China’s Innovent Biologics Inc. announced a global partnership worth up to $10.5 billion to develop cancer drugs. The deal includes a $650 million upfront payment and up to $9.85 billion in potential milestones, covering 12 early-stage, first-in-class oncology discovery and R&D programs. BioPharma Dive reported on the landmark agreement, which signals that Chinese innovation has become essential to Big Pharma’s pipelines.
This partnership is not an isolated event. Chinese biotech firms struck a record US$60 billion in cross-border licensing deals in the first quarter of 2026 alone — a 73% year-on-year surge — equaling nearly half of the US$135.7 billion in total out-licensing agreements signed in all of 2025, as reported by the South China Morning Post.
Domestic Drug Approvals Accelerate
China’s regulatory environment has evolved dramatically to support domestic innovation. The National Medical Products Administration (NMPA) has overhauled its approval process, resulting in a sharp increase in home-grown drug approvals. Of the 19 innovative drugs cleared by the NMPA so far in 2026, 15 came from domestic companies. China approved 76 innovative drugs in 2025, up from 48 in 2024, according to SCMP.
Fosun Pharma, a bellwether for the industry, invested 4.3 billion yuan (US$634 million) in innovative drug R&D in 2025 — a 16% increase from 2024 — with more than 80% of its total research budget now directed toward innovative drug development.
The Chinese government has further signaled its commitment by elevating the pharmaceutical sector to a national economic growth engine in its 2026 government work report for the first time. The “Made in China 2025” initiative, the 14th Five Year Plan, and the “Healthy China 2030” initiative all identify biotechnology as a strategic priority.
US Policy Response Intensifies
The rapid rise of Chinese biotech has triggered an escalating policy response from Washington. The BIOSECURE Act, signed into law as part of the defense budget, prohibits federal agencies and federal funding recipients from using biotechnology equipment and services from companies associated with foreign adversaries. President Trump has also signed legislation barring government agencies from contracting with certain foreign biotech service providers.
Meanwhile, the U.S. International Trade Commission has launched investigations into Chinese state support and pricing practices in the biotech sector, examining whether government subsidies and market conduct have harmed U.S. firms. BioBriefs reported that the probe could lead to tariffs or trade restrictions depending on its findings, adding that biotech companies with China exposure should expect heightened regulatory and political risk.
The Strategic Dilemma for US Pharma
American pharmaceutical companies find themselves in a complex position. On one hand, Chinese firms — supported by state subsidies — can offer substantially lower prices for novel compounds, allowing major Western companies to bypass expensive American start-ups. On the other hand, growing reliance on Chinese innovation creates supply chain vulnerabilities and national security concerns.
This tension was on full display at ASCO 2026, where Merck & Co. presented encouraging data for sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate discovered by China-based Kelun-Biotech and licensed to Merck. BioPharma Dive reported that the therapy reduced the risk of disease progression or death by 65% compared to Keytruda alone in a Phase 3 lung cancer trial. Merck has placed the drug into a sprawling Phase 3 program spanning 17 studies, underscoring how deeply Chinese innovation has become embedded in Big Pharma’s pipelines.
What Lies Ahead
The trajectory of Chinese biotech raises critical questions about the future of global pharmaceutical competition. Can Chinese firms translate their ASCO presence into FDA and European Medicines Agency approvals? Will the BIOSECURE Act and ITC probe significantly disrupt US-China biotech partnerships? And how will American pharmaceutical companies navigate the growing tension between accessing Chinese innovation and complying with new restrictions?
What is clear is that the era of unchallenged US dominance in drug development is drawing to a close. As China Daily Brief’s editorial analysis noted, the 2026 ASCO data provides “quantitative validation of China’s multi-year investment in its domestic biotech ecosystem” and suggests that “the gap between Chinese and Western innovation is closing.” For an industry that has long looked to the United States for breakthrough therapies, the message from Chicago this week is unmistakable: the center of gravity in global drug development is shifting.